



Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine

Rubino, Sebastian; Bach, Martin D.; Schober, Alexandra L.; Lambert, Ian Henry; Mongin, Alexander A.

Published in:
Frontiers in oncology

DOI:
[10.3389/fonc.2018.00142](https://doi.org/10.3389/fonc.2018.00142)

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Rubino, S., Bach, M. D., Schober, A. L., Lambert, I. H., & Mongin, A. A. (2018). Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine. *Frontiers in oncology*, 8, [142]. <https://doi.org/10.3389/fonc.2018.00142>



Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine

Sebastian Rubino^{1,2}, Martin D. Bach³, Alexandra L. Schober², Ian H. Lambert³ and Alexander A. Mongin^{2*}

¹ Department of Neurosurgery, Albany Medical Center, Albany, NY, United States, ² Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY, United States, ³ Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark

OPEN ACCESS

Edited by:

Gordon Li,
Stanford University,
United States

Reviewed by:

Vinesh Puliappadamba,
University of Texas Southwestern
Medical Center, United States
David D. Eisenstat,
University of Alberta, Canada

*Correspondence:

Alexander A. Mongin
mongina@amc.edu

Specialty section:

This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology

Received: 03 November 2017

Accepted: 18 April 2018

Published: 07 May 2018

Citation:

Rubino S, Bach MD, Schober AL, Lambert IH and Mongin AA (2018) Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine. *Front. Oncol.* 8:142. doi: 10.3389/fonc.2018.00142

Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Ubiquitously expressed volume-regulated anion channels (VRAC) are thought to play a role in cell proliferation, migration, and apoptosis. VRAC are heteromeric channel complexes assembled from proteins belonging to the leucine-rich repeat-containing 8A (LRRC8A through E), among which LRRC8A plays an indispensable role. In the present work, we used an RNAi approach to test potential significance of VRAC and LRRC8A in GBM survival and sensitivity to chemotherapeutic agents.

Methods: Primary GBM cells were derived from a human surgical tissue sample. *LRRC8A* expression was determined with quantitative RT-PCR and downregulated using siRNA. The effects of LRRC8A knockdown on GBM cell viability, proliferation, and sensitivity to chemotherapeutic agents were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and Coulter counter assays. Cell cycle progression was further explored using fluorescence-activated cell sorting analysis of propidium iodide-stained cells.

Results: Temozolomide (TMZ), carmustine, and cisplatin reduced GBM cell survival with the IC₅₀ values of ~1,250, 320, and 30 μM, respectively. Two of three tested gene-specific siRNA constructs, siLRRC8A_3 and siLRRC8A_6, downregulated *LRRC8A* expression by >80% and significantly reduced GBM cell numbers. The most potent siLRRC8A_3 itself reduced viable cell numbers by ≥50%, and significantly increased toxicity of the sub-IC₅₀ concentrations of TMZ (570 μM) and carmustine (167 μM). In contrast, the effects of siLRRC8A_3 and cisplatin (32 μM) were not additive, most likely because cisplatin uptake is VRAC-dependent. The results obtained in primary GBM cells were qualitatively recapitulated in U251 human GBM cell line.

Conclusion: Downregulation of LRRC8A expression reduces GBM cell proliferation and increases sensitivity to the clinically used TMZ and carmustine. These findings indicate that VRAC represents a potential target for the treatment of GBM, alone or in combination with the current standard-of-care.

Keywords: glioblastoma, leucine-rich repeat-containing 8A, volume-regulated anion channel, temozolomide, carmustine, cisplatin

INTRODUCTION

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults (1, 2), with an annual incidence of approximately 4 per 100,000 people and 14,000 new diagnoses per year (3). Despite extensive translational work and clinical studies, the prognosis for GBM patients remains grim. Newly diagnosed patients typically receive maximal safe surgical resection, followed by treatment with the chemotherapeutic temozolomide (TMZ) and radiation therapy (2). However, even after receiving this standard-of-care treatment, median relative survival time ranges from 13 to 15 months only, with a 2-year overall survival of 21–26% (3, 4).

Temozolomide is the most commonly used chemotherapeutic in the treatment of GBM. It is an imidazotetrazine compound that is metabolically converted to the reactive methyl diazonium cation, which in turn methylates DNA and triggers apoptotic cell death (5, 6). GBM tumor cells develop chemoresistance by upregulating methylguanine methyltransferase to remove the cytotoxic O⁶-methylguanine, or *via* selection of mismatch repair-deficient cells, which can tolerate alkylating agents (5). Additional adjuvant therapy involves the surgical implantation of Gliadel wafers, which provide local delivery of the chemotherapeutic polymer carmustine (bis-chloroethylnitrosourea) (7, 8). Gliadel wafers are used less frequently because systematic review of clinical data indicates that they only increase survival marginally and are associated with high-complication rates (9). Limited efficacy of existing therapies creates an urgent need for development of novel treatment modalities.

Ion channels are frequently discussed as possible targets for cancer treatment due to their many roles in tumor biology [reviewed in Ref. (10–12)]. In the present study, we focused on the ubiquitously expressed volume-regulated chloride/anion channels (VRAC). VRAC were first functionally discovered in epithelial and immune cells (13, 14), and soon thereafter detected in numerous other cell types, including rat glioma cells (15–19). Although the primary function of VRAC is cell volume regulation, these channels are believed to play a role in cell proliferation, migration, and apoptosis, in normal and malignant cells [reviewed in Ref. (17, 19–21)]. Due to their purported significance in proliferation and migration, VRAC have long been considered a potential therapeutic target. However, the direct evidence for their contribution to these processes has been lacking due to limited specificity of pharmacological VRAC blockers, and because the molecular identity of VRAC remained elusive for nearly three decades (19).

In 2014, two groups independently identified proteins of the leucine-rich repeat-containing 8A (LRRC8A) as components of the heteromeric VRAC (22, 23). LRRC8A is mandatory for VRAC activity but this subunit has to be heteromerized with at least one additional protein from the same LRRC8 family to produce a functional, presumably hexameric channel complex (23). Our laboratory was the first to establish the indispensable

role of LRRC8A in forming VRAC in rat astrocytes (24), and we subsequently found that in astroglial cells there are at least two functionally distinct LRRC8A-containing VRAC heteromers (25). As GBM tumors are thought to originate from anaplastic astroglia or glial progenitor cells (26, 27), the prior work prompted us to test if the LRRC8-containing channels are important for GBM cell proliferation. Furthermore, we explored whether targeting VRAC could interfere with the effect of the clinically used chemotherapeutic agents, TMZ, and carmustine. Given the prior findings that the LRRC8A/LRRC8D-containing VRAC facilitate cisplatin sensitivity in several cell types (28, 29), we used cisplatin as a reference compound.

MATERIALS AND METHODS

Materials and Reagents

Temozolomide, carmustine, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Millipore-Sigma (St. Louis, MO, USA). Cisplatin was acquired from Tocris/Bio-Techne (Minneapolis, MN, USA). Lipofectamine RNAiMax, DNase-free RNase A, and 1 mg/ml stock solution of propidium iodide in water were from Thermo Fisher Scientific (Waltham, MA, USA). Cell culture components—fetal bovine serum (FBS), glutamine-containing Earl's minimal essential medium (MEM, cat. # 10,293), OptiMEM, penicillin plus streptomycin, and the recombinant protease TrypLE Express, all of the Gibco brand—were from Thermo Fisher Scientific. Quantitative PCR primers for *LRRC8A* and the housekeeping genes *RPL13a*, *RPS20*, and *GAPDH*, gene-specific siRNAs and negative control Allstars siRNA were all purchased from Qiagen (Germantown, MD, USA). All other salts and reagents were purchased from Millipore-Sigma, and were of analytical grade, unless specified otherwise.

Carmustine and TMZ were dissolved under sterile conditions in dimethyl sulfoxide (DMSO) to stock concentrations of 30 and 150 mM, respectively, and stored at -20°C until used in experiments. Cisplatin was dissolved in sterile Dulbecco's phosphate-buffered saline (DPBS) to produce 3.3 mM stock solution, and stored at -20°C until used.

Primary Culture of GBM and U251 MG Cell Line

Primary GBM cells, which had been characterized in our prior work, were prepared from a surgical GBM tissue sample as previously described (30). The specimen was obtained under the protocol approved by the Albany Medical Center Institutional Review Board, with written patient consent. The GBM origin of tissue was histologically confirmed by a pathologist at the time of resection. Briefly, tumor tissue was washed with ice-cold $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free phosphate-buffered saline (PBS, pH 7.4), dissected into small pieces, digested in the solution of 0.125% trypsin/0.015% EDTA, which additionally contained DNase I, and further gently dissociated using trituration with a fire-polished glass Pasteur pipette. The dissociated cells were initially propagated in T75 cell culture flasks in DMEM plus 20% FBS supplemented with 100 U/ml penicillin, and 100 $\mu\text{g}/\text{ml}$

Abbreviations: DPBS, Dulbecco's phosphate-buffered saline; FBS, fetal bovine serum; LRRC8A, leucine-rich repeat-containing 8A; MEM, minimal essential medium; VRAC, volume-regulated anion channels.

streptomycin. After two passages, the FBS content was reduced to 10%, and penicillin and streptomycin concentrations were reduced to 50 U/ml and 50 µg/ml, respectively. Propagated cells were removed from the substrate using recombinant protease TrypLE, transferred into freezing medium, and stored in liquid nitrogen.

For the presented work, GBM cells were re-plated in MEM supplemented with 10% FBS, 50 µg/ml penicillin, and 50 µM streptomycin, and grown in T75 flasks in the humidified atmosphere of 5% CO₂/balance air at 37°C. Cells were periodically passaged after they reached 70–90% confluence, or used for experimental procedures as described below. All presented experiments were carried out with cells in passages 3 through 13.

For comparative purposes, we used human GBM cell line U251 MG (hereafter referred to as U251). This cell line is originally derived in the early 1970s from a male patient with malignant grade III–IV astrocytoma (31). U251 utilized in this study was a gift of Dr. Michael G. Kaplitt. The initial passage of these cells is unknown. Among other features, U251 express a mutated p53 protein, which is typical for GBM tumors, and they are positive for the astroglial cell marker, glial fibrillary acidic protein (GFAP) (32). Expression of human cell markers and GFAP immunoreactivity has been confirmed in our prior published work (33). U251 cells were propagated in MEM supplemented with 10% FBS and antibiotics, as described above. The cultivation and assay conditions were the same as for primary GBM cells.

Quantitative RT-PCR (qRT-PCR) Analysis of Gene Expression

Relative expression of *LRRC8A* mRNA and the efficacy of siRNA gene knockdowns were determined using qRT-PCR. GBM cells were plated in 60-mm Petri dishes. Non-transfected or siRNA-transfected cells were grown for 48 h. mRNA species were isolated using the RNeasy-4PCR kit (Thermo Fisher Scientific) according to the manufacturer's protocol. mRNA was converted to cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). Human *LRRC8A* expression levels were determined using quantitative PCR primers (Qiagen cat. #QT01023302) and SYBR Green master mix (Bio-Rad). The expression levels were normalized within each sample to the housekeeping genes, the ribosomal proteins *RPL13A* (cat.# QT00089915), and *RPS20* (cat.# QT01666847). Real-time detection of PCR products was done using a CFX96 Real-Time PCR setup (Bio-Rad).

siRNA Transfections

Glioblastoma cell transfection was performed as previously described (24). Briefly, primary GBM or U251 cells were plated in 24-well cell culture plates or 60-mm Petri dishes (10,000 cells per well or ~150,000 cells per Petri dish) and grown for 1 (U251) or 3 days (primary GBM) prior to transfection. The cell culture medium was removed and cells were washed with the serum-free OptiMEM, before transfection in the same medium with either negative control siRNA or siRNA targeting *LRRC8A*, using the Lipofectamine RNAiMax transfecting agent (Invitrogen/Thermo Fisher Scientific, Waltham, MA,

USA). We used three different gene-specific siRNA constructs: siLRRC8A_3 (Hs_LRRC8A_3; Qiagen cat.# SI04251807), siLRRC8A_4 (Hs_LRRC8A_4; cat.# SI04327001), and siLRRC8A_6 (Hs_LRRC8A_6; cat.# SI05006036), and AllStars scrambled siRNA as a negative control. siRNA-transfection reagent complexes were prepared in OptiMEM per the manufacturer's instructions, and then further diluted with OptiMEM to the final siRNA concentration of 50 nM and added to the wells. After 4 h incubation with siRNA complexes, threefold excess of the FBS-containing cell culture medium was added on the top, and cells were further grown for ~44 h prior to adding chemotherapeutic agents. 48 h after adding chemotherapeutics (four full days of transfection) changes in cell proliferation and viability were determined using an MTT assay.

MTT Assay

The MTT cell proliferation and viability assay was conducted as previously described (33). Briefly, GBM cells were plated into 24-well plates at either “lower” (10,000 cells/well) or “higher” (40,000 cells/well) density and allowed to grow for one (U251) or three (primary GBM) days prior to experimental treatments. Cells were subsequently treated with chemotherapeutic agents or transfected with siRNA as described above. After completing cell treatments, cell culture medium was removed by aspiration, and cells were washed once with the chemically defined basal solution containing (in millimolar): 135 NaCl, 3.5 KCl, 1.2 MgSO₄, 1.3 CaCl₂, 1.2 KH₂PO₄, 10 HEPES, and 10 D-glucose (pH 7.4, adjusted with NaOH). Subsequently, the basal medium was substituted with the same solution additionally containing 0.5 mg/ml MTT. Depending on cell density, MTT incubation lasted 1–2 h. The MTT solution was removed by inverting the plate without washing. The metabolically formed formazan crystals were dissolved using 1 ml of acidified isopropanol and the absorbance of the solution in each well was determined at 562 nm, using a BioTek ELx800 plate reader (Winooski, VT, USA).

Coulter Counter Assay

To independently verify the MTT assay results, we directly counted GBM and U251 cells using a Coulter counter as described before (33). Briefly, cells grown in 24-well plates at plating density as above were detached from the substrate using a recombinant protease TrypLE and resuspended in the ISOTON II diluent (Beckman Coulter, Miami, FL, USA). Cell numbers were determined using a Z2 series Coulter counter (Beckman Coulter), with the detection cell diameter limits set at 7–25 µm.

Flow Cytometry Cell Cycle Analysis

Cell cycle analysis was performed by quantitation of the relative DNA content using fluorescence-assisted cell sorting (FACS) of propidium iodide-stained cells as originally described by Krishan (34) with further extension for analysis of apoptosis (35, 36). Briefly, cells were plated and treated in 12-well plates as described for MTT assays. They were detached from the substrate with TrypLE, fixed for 20 min at room temperature (20°C) in a hypotonic solution containing 2% paraformaldehyde, and rinsed from the fixative by sedimentation in PBS. Fixed cells were stained in

the PBS solution containing 1 mg/ml DNase-free RNase A and 10 μ g/ml propidium iodide for 30 min at room temperature. Single cell propidium iodide fluorescence was quantified using an FACSCanto flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) and analyzed with FlowJo 7.5 software (FlowJo, LLC., Ashland, OR, USA).

Statistical Analysis

All data are presented as the mean values \pm SEM, after normalization to control values within the same experiment. Because of normalization, all comparisons to control values were performed using one-tailed *t*-test, followed by the Bonferroni *post hoc* correction for multiple comparisons. When applicable, comparisons between experimental groups were done using two-tailed *t*-test with Bonferroni *post hoc* correction. Origin 8.1 software (OriginLab, Northampton, MA, USA) was used for statistical analyses. A *p*-value of <0.05 was considered statistically significant.

RESULTS

LRRC8A Gene Expression and Validation of siRNA Tools


In order to test functional significance of the LRRC8A-containing VRAC, we initially verified its expression in GBM cells and validated LRRC8A-targeting siRNA constructs using quantitative real-time reverse transcriptase PCR (qRT-PCR) approach. In the GBM cell line used in the present study, LRRC8A mRNA expression was $0.27 \pm 0.17\%$ when normalized to the housekeeping gene RPL13A within the same cDNA samples ($n = 5$ independent cell preparations). These values are comparable with those which we found in primary astroglial cells isolated from the rodent brain (25). We next tested three different siRNA

constructs for their ability to knockdown LRRC8A expression. In order of potency, siLRRC8A_3, siLRRC8A_6, and siLRRC8A_4 reduced the LRRC8A mRNA levels by 84% ($p < 0.001$), 82% ($p < 0.01$), and 73% ($p < 0.001$), respectively (Figure 1A). We further tested siLRRC8A_3 and siLRRC8A_6 for their effects on cell proliferation and found that siLRRC8A_3 and siLRRC8A_6 decreased GBM proliferation by 55% ($p < 0.05$) and 21% ($p < 0.05$), respectively (Figure 1B). The most efficacious siLRRC8A_3 was used in all subsequent cell viability assays.

Characterization of GBM Sensitivity to Chemotherapeutic Agents

Glioblastoma cells are known to have variable sensitivity to chemotherapeutic agents and to develop chemoresistance (37–40). As we used a primary GBM cell line, we first performed a dose–response study to determine IC₅₀ values for TMZ, carmustine, and cisplatin. We included cisplatin as an experimental control, because it enters cancer cells *via* VRAC (28, 29).

As shown in Figure 2, all three chemotherapeutic agents reduced viability of GBM cells in a dose-dependent manner. Cisplatin showed the highest toxicity, whereas TMZ was least toxic. The IC₅₀ values for cisplatin, carmustine, and TMZ, were approximately 30, 320, and 1,250 μ M, respectively (Figure 2). Due to TMZ and carmustine's hydrophobicity, their stock solutions were prepared in DMSO before addition to experimental media. However, even in DMSO, TMZ and carmustine have a low solubility. Consequently, the three highest tested dosages of these agents were delivered with DMSO levels between 0.5 and 1.5%. To control for vehicle toxicity, we tested the effect of DMSO on cell viability. DMSO alone reduced cell numbers, in a dose-dependent manner (Figure S1 in Supplementary Material). These findings are consistent with the prior reports that in some cell types proliferation can be inhibited by DMSO levels as low as 0.1% (41, 42). To reduce DMSO toxicity, further individual



proliferation experiments were carried out at the sub-IC₅₀ levels of TMZ (570 μM) and carmustine (167 μM) and 0.38% DMSO was used as a vehicle control. Cisplatin was dissolved in DPBS, and further tested at the IC₅₀ concentration (32 μM). No vehicle control was necessary in the latter case.




FIGURE 2 | Dose-dependent effects of the chemotherapeutic agents temozolomide (TMZ), carmustine [bis-chloroethylnitrosourea (BCNU)], and cisplatin on viability of primary glioblastoma (GBM) cells. GBM cells were treated with various concentrations of chemotoxic agents and the relative cell numbers were compared 48 h later using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Each experimental point represents the mean values ± SE of four to eight independent measurements, which were accumulated in four independent experiments and normalized to an average MTT signal in non-treated cells within the same experiment. The three lowest concentrations of BCNU were tested two times.

LRRC8A Knockdown Decreases GBM Proliferation and Increases Sensitivity to TMZ and Carmustine, but Not Cisplatin

As illustrated in **Figures 3–5**, knockdown of *LRRC8A* consistently decreased GBM cell numbers by ~50%, pointing to the likely importance of VRAC in GBM cell proliferation. To explore if *LRRC8A* knockdown impacts sensitivity of GBM cells to clinically used chemotherapeutic agents, we tested the effects of TMZ and carmustine in conjunction with the *LRRC8A*-targeting siRNA. As seen in **Figure 3A**, downregulation of *LRRC8A* strongly and significantly reduced MTT signal by 59% ($p < 0.01$), while TMZ was less potent (27% reduction, $p < 0.05$). The effect of combining *LRRC8A* siRNA with TMZ approached the level of additivity of individual treatments (73%, $p < 0.01$, **Figure 3A**). Although the MTT assay fairly faithfully reflects relative cell numbers (43), we and others have encountered situations where formazan production was reduced without changes in cell viability [see, for example, (44)]. In order to validate MTT results, we repeated cell treatments and directly counted cells using a Coulter counter. As shown in **Figure 3B**, the results of electronic cell counts were quantitatively very similar: 49, 21, and 79% for *LRRC8A* siRNA ($p < 0.01$), TMZ ($p < 0.05$), and their combination ($p < 0.001$), respectively. These findings reaffirm the conclusions on reduced cell proliferation after *LRRC8A* knockdown, and additivity of siRNA and TMZ effects.

In the next series of experiments, we observed very similar phenomena in GBM cells treated with another clinically utilized chemotherapeutic, carmustine. Specifically, siRNA, carmustine, and their combination decreased cell viability by 47% ($p < 0.05$), 22% ($p < 0.05$), and 64% ($p < 0.05$), respectively (**Figure 4A**). In the latter case, due to experimental variability there was only a trend for additive actions of carmustine with siRNA transfection ($p < 0.1$). In the Coulter counter experiments shown in **Figure 4B**,






FIGURE 3 | Effects of temozolomide (TMZ) and leucine-rich repeat-containing 8A (*LRRC8A*) siRNA on viability and proliferation of glioblastoma (GBM) cells determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (**A**) or Coulter counter (**B**) assays. GBM cells were transfected with siLRRC8A_3 or negative control siRNA (siNC). 48 h post-transfection cells were additionally treated with 570 μM TMZ. Relative levels of cell proliferation were determined 48 h after addition of TMZ (96 h post-transfection with siRNA). Non-transfected cells (NTF) were used in MTT assays as an additional internal control. The data are the mean values ± SE of three independent experiments performed in triplicates ($n = 3$) for MTT assays, or four independent transfections ($n = 4$) in Coulter counter experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. cells transfected with siNC. † $p < 0.05$, †† $p < 0.01$, ††† $p < 0.001$, within the group effect of TMZ vs. siRNA or mock treatment alone. ## $p < 0.01$, ### $p < 0.001$, TMZ effect in cells treated with siNC vs. cells treated with siLRRC8A_3.



latter assays, the additive toxicity of the LRRC8A knockdown and carmustine was very clear and statistically significant.

We additionally tested the chemotherapeutic agent cisplatin. This was important because prior work in the field established that the LRRC8A/LRRC8D-containing VRAC is largely responsible for cisplatin uptake (28, 29). In contrast to TMZ and carmustine, downregulation of LRRC8A eliminated sensitivity of GBM cells to cisplatin. The individual treatments of siRNA or cisplatin reduced GBM cell viability by 60% ($p < 0.01$) and 56% ($p < 0.01$), respectively (Figure 5). Combination of siRNA plus cisplatin did not produce significant additional effect, reducing cell viability by 62% (Figure 5, $p = 0.38$, compared with siRNA alone; $p = 0.32$, compared with cisplatin alone).

Cell Cycle Analysis in Cells Treated With the LRRC8A siRNA and Chemotherapeutics

In order to gain insight into potential mechanisms responsible for the impact of LRRC8A downregulation on cell viability and proliferation, we performed FACS analysis of propidium iodide-stained cells (34–36). The results of these experiments are presented in Figure 6. LRRC8A knockdown produced statistically significant increases in cells undergoing the S phase of mitosis (~twofold increases, $p < 0.05$, Figure 6G). We also found a not-significant trend for increases in the apoptotic cell numbers (Figure 6E). These changes were associated with matching decreases in the G₁/G₀ cell population (Figure 6F). When cells were treated with a combination of siRNA and chemotherapeutic agents, the resulting changes were much more profound. Both TMZ and carmustine produced three- to fourfold increases in the G₂/M population (Figure 6F), similar three- to fourfold increases in S phase cells (Figure 6G), and a

the same treatments reduced cell numbers in a nearly identical fashion: 49% ($p < 0.01$), 21% ($p < 0.05$), and 79% ($p < 0.001$), for siRNA, carmustine, and their combination, respectively. In these

not significant trend of four- to sevenfold increases in apoptotic cell numbers (Figure 6E).

Effect of the LRRC8A Knockdown on Viability and Cell Cycle Distribution of U251 Cells

For comparative purposes, we recapitulated cell viability experiments in the U251 GBM cell line. We treated U251 cells with the LRRC8A-targeting siRNA with or without the chemotherapeutic agents, 570 μM TMZ or 57 μM carmustine. As a control, cells were treated in the same fashion but with scrambled siRNA. As seen in Figure 7A, under “control” conditions (negative control siRNA), TMZ reduced cell viability by ~25% ($p < 0.001$), while carmustine was less effective (trend for 12% inhibition, $p = 0.055$, after Bonferroni correction). In contrast, treatment with LRRC8A siRNA potently reduced cell numbers by ~55% ($p < 0.001$). When the LRRC8A siRNA was combined with TMZ or carmustine, increase in inhibition of cell viability was not statistically significant ($p = 0.118$ and 0.108 , respectively, after Bonferroni correction, but see significant additivity in Figure 7B). When cell viability experiments were replicated using Coulter counter assays, the results were qualitatively similar (Figure 7B). The only difference was the weaker reductions in cell viability by the LRRC8A siRNA, perhaps reflecting less effective knockdown of the LRRC8A protein.

Fluorescence-assisted cell sorting cell cycle assays in U251 cells showed the patterns of distribution of among the three mitotic phases and apoptotic population, which were similar to the results in primary GBM. However, we found a number of quantitative and qualitative differences. In the control treatment group, we found more cells moving through S and G₂/M phases, which likely reflects the higher proliferative potential in this cell line, when compared to primary GBM. An additional difference was the presence of polyploid cells, which had been reported in the previous studies [see, for example, (45)]. Although we identified no obvious quantitative difference between control and the LRRC8A siRNA-treated cells, combination of siRNA with chemotherapeutic agents strongly increased the S phase and G₂/M phase populations, as well as enrichment of apoptotic cells (see representative graphs in Figures 7C1–4 and quantitation in Figures 7D1–4). There were also increases in polyploid cell numbers.

DISCUSSION

The present work was instigated to explore the functional significance of the LRRC8A-containing VRAC in human gliomas. Two major findings of our work are: (i) downregulation of LRRC8A strongly decreases numbers of GBM cells, suggesting the importance of the LRRC8A-containing VRAC for their proliferation





FIGURE 6 | Fluorescence-assisted cell sorting (FACS) analysis of cell proliferation in glioblastoma (GBM) cells treated with leucine-rich repeat-containing 8A (LRRC8A) siRNA and chemotherapeutics agents. DNA content in fixed and permeabilized GBM cells was determined after staining with propidium iodide using FACS analysis, as described in Section “Materials and Methods.” (A–D) Representative FACS data in cells treated with negative control siRNA (siNC), LRRC8A siRNA (siA₃), or their combination, as specified. (E–H) Quantitation of FACS data for cells segregated in apoptotic (E), G₁–G₀ (F), S phase (G), and G₂/M (H) populations. The data are the mean values ± SE of three independently transfected cell populations. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, vs. cells transfected with siNC.



and viability; (ii) downregulation of LRRC8A increases sensitivity of primary GBM cells to the clinically used chemotherapeutic agents TMZ and carmustine, indicating that VRAC can be targeted for therapeutic purposes.

Volume-regulated anion channels activity is firmly associated with the ability of cells to regulate their volume, and is reported to play a role in cell proliferation, migration, apoptosis, cell excitability, and transepithelial ion transport (17, 19,

21, 46). However, the collective evidence for these functional roles was rather weak due to the unknown molecular identity of VRAC and limited selectivity of available pharmacological tools. In 2014, two breakthrough publications independently identified VRAC as heteromeric channels assembled from the proteins belonging to the LRRC8 family (22, 23). Prior to this discovery, the idea of VRAC involvement in cell proliferation was supported by two types of observations: (i) non-specific

VRAC inhibitors were found to strongly limit cell proliferation in numerous cell types, including malignant cells, and (ii) in dividing cells, the density of VRAC currents fluctuated depending on the cell cycle stage (47–53). We believe that the present work is the first study to use a gene-specific RNAi approach to validate the significance of LRRC8A in cell proliferation. The inhibitory effects of the LRRC8A knockdown were quantitatively similar in primary GBM cells and U251 GBM cell line. This was recapitulated with two different cell proliferation and viability assays, e.g., electronic cell counting and MTT assay. Changes in absolute cell numbers (Coulter counter) point to the reduced proliferation, but we cannot exclude other mechanisms (see discussion below).

The idea that VRAC activity is involved in control of cell proliferation is important in the context of cancer cell biology. The role of VRAC in proliferative control is supported by the prior studies utilizing pharmacological inhibitors. For example, VRAC blockers arrest small cell lung cancer, cervical cancer, and T-lymphoma cells in G₀/G₁ phase, based on the results of cell cytometry and changes in the expression levels of cyclins and CDK kinases (50, 53). In astroglial cells, which share cell lineage with GBM, the VRAC blocker DCPIB also causes G₀/G₁ arrest due to cell failure to pass the G₁/S checkpoint (54). The latter conclusion has been derived using FACS analysis, BrdU labeling, and assays of cyclin D1 and CDK4 expression (54). In our present work, knockdown of LRRC8A caused ~twofold enrichment in cells allocated in the synthesis (S) phase of mitosis, and quantitatively similar but not statistically significant increases in the apoptotic population. These data differ from prior findings in astrocytes and do not provide a clear picture of the cell cycle arrest. The discrepancies may be explained by differences in cell type or treatment (siRNA vs. channel blocker). It is also possible that our data were skewed by the loss of cell subpopulations during fixation and staining procedures. Further work is needed to verify these findings and directly compare the effects of the LRRC8A knockdowns to the actions of pharmacological blockers.

As downregulation of the LRRC8A expression strongly reduced cell GBM cell numbers, our next important question was if targeting VRAC could enhance the effect of the chemotherapeutics, TMZ and carmustine, which are currently used in clinical settings. The outcome of the combined treatment (siRNA plus chemotherapeutics) was difficult to predict based on the existing knowledge in the field. Prior to discovery of LRRC8 proteins, development of resistance to cisplatin and few other chemotherapeutic agents has been associated with dramatic downregulation of VRAC activity and decreased ability of cells to regulate their volume (55–57). Recently, the platinum-based chemotherapeutics, cisplatin, and carboplatin have been found to accumulate in cancer cells *via* the LRRC8A/LRRC8D-containing heteromers, which were downregulated with the development of chemoresistance (28, 29). An additional complication of knocking down LRRC8A in tumor cells, which is unrelated to the transport of chemotoxic substances, arises from the established role of VRAC in apoptosis. VRAC contributes to initial apoptotic cell volume decrease, and is required for progression to the later stages of apoptosis (46, 58–61).

Keeping these caveats in mind, we explored if LRRC8A knockdown would lead to undesirable chemoresistance or apoptotic resistance in GBM cells. Fortunately, we did not find that to be the case. Downregulation of LRRC8A expression in primary GBM cells produced additive toxic effects with TMZ and carmustine. In FACS assays, combinatory treatment with siRNA and chemotherapeutics consistently increased cell numbers in S and G₂/M phases of mitosis, consistent with well-known G₂/M arrest caused by TMZ and carmustine (62, 63), but also significant increases in numbers of apoptotic cells.

To ensure that our observations in the primary GBM cell culture are broadly applicable to other types of GBM cells, we evaluated the effects of LRRC8A knockdown on the viability of the human U251 cells, one of the most widely used GBM cell lines. Much like in the primary GBM cultures, knockdown of LRRC8A reduced U251 cell numbers by >50% and was significantly more potent than treatment with either TMZ or carmustine alone. When we combined the LRRC8A siRNA with chemotherapeutics, our assays again showed a strong trend for additivity in the toxic effects of both treatments, and were far superior to the chemotherapeutics alone. Combinatory treatment facilitated G₂/M arrest of GBM cells and was associated with an increase in apoptotic cell numbers. Therefore, U251 results reiterate our GBM data that targeting LRRC8A can be combined with existing chemotherapies.

Our understanding of GBM biology and pathophysiology continues to evolve due to advances in the fields of GBM genetics, epigenetics, and proteomics (64–66). As already mentioned, ion channels have been linked to many aspects of tumor pathophysiology and, therefore, receive increasing attention as potential biomarkers and/or therapeutic targets (10, 67, 68). GBM proliferation, migration, and invasion are dependent on expression and activity of several types of K⁺, Ca²⁺, non-selective cation, and Cl⁻ channels (11, 30, 69–71). Among Cl⁻ channels, ClC-2, -3, and -5, and chloride intracellular channels CLIC-1 and CLIC-4 have been implicated in GBM cell migration or associated with negative clinical outcomes (72, 73). Here, we add the pore-forming subunit of VRAC, LRRC8A, to the list of ion channel proteins potentially responsible for the aggressive nature of GBM. Importantly, we tested pathological relevance of the LRRC8A-containing VRAC in the primary GBM cells, in order to avoid limitations associated with using over-passaged glioma cell lines.

In the context of development of new treatment modalities, our present findings can be summarized as follows: (a) compared with TMZ and carmustine, the LRRC8A knockdown was *twice* as effective in reducing GBM cell numbers (20–25 vs. 50–60% for chemotherapeutic agents and siRNA, respectively). (b) The combinatory treatment was *three times* more effective in reducing cell numbers, when compared with TMZ or carmustine alone (the combined toxicity reached 65–80% levels). Due to the diverse nature of GBM, our work will need to be further corroborated in additional GBM cell lines and in animal GBM models. These limitations notwithstanding, the LRRC8A-containing VRAC appears to represent a new target for the treatment of GBM, alone or in combination with the current standard-of-care.

ETHICS STATEMENT

Primary glioblastoma cells, which had been characterized in our prior work, were prepared from a surgical GBM tissue sample as previously described (30). The specimen was obtained under the protocol approved by the Albany Medical Center Institutional Review Board, with written patient consent. The GBM origin of tissue was histologically confirmed by a pathologist at the time of resection.

AUTHOR CONTRIBUTIONS

SR, MB, IL, and AM conceived and designed the project. SR, MB, and AS conducted the research. SR, MB, AS, and AM analyzed the data. SR, MB, AS, IL, and AM wrote or edited the manuscript. All authors agree to be collectively responsible for the work.

ACKNOWLEDGMENTS

The authors thank Drs. Julie G. Pilitsis and Alan S. Boulos for their support of this project. The authors are also grateful to Drs. Yu-Hung Kuo and Iskandar F. Abdullayev for their critical

contributions to the prior isolation and characterization of the GBM cell line, Drs. Carlos M. de Noronha and Danielle Califano for an expert advice on cell cycle analysis, Corinne S. Wilson for experimental help and critical reading of the manuscript, and Dr. Michael G. Kaplitt for the gift of U251 cells.

FUNDING

This work was supported in part by NIH grant R01 NS061953 (to AM) and translational funds provided by the Albany Medical College.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at <https://www.frontiersin.org/articles/10.3389/fonc.2018.00142/full#supplementary-material>.

FIGURE S1 | Effects of the vehicle agent dimethyl sulfoxide (DMSO) on proliferation of glioblastoma (GBM) cells. GBM cells were grown in the presence of indicated concentrations of DMSO, and their relative proliferation rates were determined 48 h after addition of the tested agent with an MTT assay. The data are the mean values \pm SE of four independent experiments. * $p < 0.05$ vs. control cells grown in the absence of DMSO.

REFERENCES

- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* (2007) 114:97–109. doi:10.1007/s00401-007-0278-6
- Preusser M, de RS, Wohrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. *Ann Neurol* (2011) 70:9–21. doi:10.1002/ana.22425
- Majewska P, Ioannidis S, Raza MH, Tanna N, Bulbeck H, Williams M. Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study. *CNS Oncol* (2017) 6(4):307–13. doi:10.2217/cns-2017-0001
- Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. *J Neurooncol* (2012) 107:207–12. doi:10.1007/s11060-011-0738-7
- Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. *Curr Mol Pharmacol* (2012) 5:102–14. doi:10.2174/1874467211205010102
- Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. *Oncogene* (2007) 26:186–97. doi:10.1038/sj.onc.1209785
- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. *Neuro Oncol* (2003) 5:79–88. doi:10.1093/neuonc/5.2.79
- McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. *J Neurosurg* (2009) 110:583–8. doi:10.3171/2008.5.17557
- Bregy A, Shah AH, Diaz MV, Pierce HE, Ames PL, Diaz D, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. *Expert Rev Anticancer Ther* (2013) 13:1453–61. doi:10.1586/14737140.2013.840090
- Kunzelmann K. Ion channels and cancer. *J Membr Biol* (2005) 205:159–73. doi:10.1007/s00232-005-0781-4
- Turner KL, Sontheimer H. Cl⁻ and K⁺ channels and their role in primary brain tumour biology. *Philos Trans R Soc Lond B Biol Sci* (2014) 369:201300951. doi:10.1098/rstb.2013.0095
- Hoffmann EK, Lambert IH. Ion channels and transporters in the development of drug resistance in cancer cells. *Philos Trans R Soc Lond B Biol Sci* (2014) 369:201301091. doi:10.1098/rstb.2013.0109
- Cahalan MD, Lewis RS. Role of potassium and chloride channels in volume regulation by T lymphocytes. *Soc Gen Physiol Ser* (1988) 43:281–301.
- Hazama A, Okada Y. Ca²⁺ sensitivity of volume-regulatory K⁺ and Cl⁻ channels in cultured human epithelial cells. *J Physiol* (1988) 402:687–702. doi:10.1113/jphysiol.1988.sp017229
- Jackson PS, Strange K. Volume-sensitive anion channels mediate swelling-activated inositol and taurine efflux. *Am J Physiol* (1993) 265:C1489–500. doi:10.1152/ajpcell.1993.265.6.C1489
- Jackson PS, Morrison R, Strange K. The volume-sensitive organic osmolyte-anion channel VSOAC is regulated by nonhydrolytic ATP binding. *Am J Physiol* (1994) 267:C1203–9. doi:10.1152/ajpcell.1994.267.5.C1203
- Nilius B, Eggermont J, Voets T, Buyse G, Manolopoulos V, Droogmans G. Properties of volume-regulated anion channels in mammalian cells. *Prog Biophys Mol Biol* (1997) 68:69–119. doi:10.1016/S0079-6107(97)00021-7
- Okada Y. Volume expansion-sensing outward-rectifier Cl⁻ channel: fresh start to the molecular identity and volume sensor. *Am J Physiol Cell Physiol* (1997) 273:C755–89. doi:10.1152/ajpcell.1997.273.3.C755
- Pedersen SF, Okada Y, Nilius B. Biophysics and physiology of the volume-regulated anion channel (VRAC)/volume-sensitive outwardly rectifying anion channel (VSOR). *Pflugers Arch* (2016) 468:371–83. doi:10.1007/s00424-015-1781-6
- Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E, et al. Functional significance of cell volume regulatory mechanisms. *Physiol Rev* (1998) 78:247–306. doi:10.1152/physrev.1998.78.1.247
- Hoffmann EK, Lambert IH, Pedersen SF. Physiology of cell volume regulation in vertebrates. *Physiol Rev* (2009) 89:193–277. doi:10.1152/physrev.00037.2007
- Qiu Z, Dubin AE, Mathur J, Tu B, Reddy K, Miraglia LJ, et al. SWELL1, a plasma membrane protein, is an essential component of volume-regulated anion channel. *Cell* (2014) 157:447–58. doi:10.1016/j.cell.2014.03.024
- Voss FK, Ullrich F, Munch J, Lazarow K, Lutter D, Mah N, et al. Identification of LRRc8 heteromers as an essential component of the volume-regulated anion channel VRAC. *Science* (2014) 344:634–8. doi:10.1126/science.1252826
- Hyzinski-Garcia MC, Rudkouskaya A, Mongin AA. LRRc8A protein is indispensable for swelling-activated and ATP-induced release of excitatory amino acids in rat astrocytes. *J Physiol* (2014) 592:4855–62. doi:10.1113/jphysiol.2014.278887

25. Schober AL, Wilson CS, Mongin AA. Molecular composition and heterogeneity of the LRRC8-containing swelling-activated osmolyte channels in primary rat astrocytes. *J Physiol* (2017) 595:6939–51. doi:10.1113/JP275053
26. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. *N Engl J Med* (2005) 353:811–22. doi:10.1056/NEJMra043666
27. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. *Clin Cancer Res* (2013) 19:764–72. doi:10.1158/1078-0432.CCR-12-3002
28. Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. *EMBO J* (2015) 34:2993–3008. doi:10.15252/embj.201592409
29. Sorensen BH, Dam CS, Sturup S, Lambert IH. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. *J Inorg Biochem* (2016) 160:287–95. doi:10.1016/j.jinorgbio.2016.04.004
30. Motiani RK, Hyzinski-Garcia MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. *Pflugers Arch* (2013) 465:1249–60. doi:10.1007/s00424-013-1254-8
31. Westermark B, Ponten J, Hugosson R. Determinants for the establishment of permanent tissue culture lines from human gliomas. *Acta Pathol Microbiol Scand A* (1973) 81:791–805.
32. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. *J Natl Cancer Inst* (1997) 89:1036–44. doi:10.1093/jnci/89.14.1036
33. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH. Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation. *PLoS One* (2010) 5:e12304. doi:10.1371/journal.pone.0012304
34. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. *J Cell Biol* (1975) 66:188–93. doi:10.1083/jcb.66.1.188
35. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Methods* (1991) 139:271–9. doi:10.1016/0022-1759(91)90198-0
36. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nat Protoc* (2006) 1:1458–61. doi:10.1038/nprot.2006.238
37. Wedge SR, Porteus JK, May BL, Newlands ES. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. *Br J Cancer* (1996) 73:482–90. doi:10.1038/bjc.1996.85
38. Calogero A, Porcellini A, Lombardi V, Fabbiano C, Arcella A, Miscusi M, et al. Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression. *Cancer Cell Int* (2011) 11:5. doi:10.1186/1475-2867-11-5
39. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multi-forme therapy and mechanisms of resistance. *Pharmaceuticals (Basel)* (2013) 6:1475–506. doi:10.3390/ph6121475
40. Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N. The oxidometabolic driver ATF4 enhances temozolomide chemo-resistance in human gliomas. *Oncotarget* (2017) 8:51164–76. doi:10.18632/oncotarget.17737
41. Pal R, Mamidi MK, Das AK, Bhonde R. Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential of human embryonic stem cells. *Arch Toxicol* (2012) 86:651–61. doi:10.1007/s00204-011-0782-2
42. Oz ES, Aydemir E, Fiskin K. DMSO exhibits similar cytotoxicity effects to thalidomide in mouse breast cancer cells. *Oncol Lett* (2012) 3:927–9. doi:10.3892/ol.2012.559
43. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell viability assays. In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, editors. *Assay Guidance Manual [Internet]*. Bethesda, MD: Eli Lilly and the National Center for Advancing Translational Sciences (2004). p. 1–31.
44. Akimova OA, Mongin AA, Hamet P, Orlov SN. The rapid decline of MTT reduction is not a marker of death signaling in ouabain-treated cells. *Cell Mol Biol* (2006) 52:71–7. doi:10.1170/T763
45. Schilling SH, Hjelmeland AB, Radloff DR, Liu IM, Wakeman TP, Fielhauer JR, et al. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. *J Biol Chem* (2009) 284:25160–9. doi:10.1074/jbc.M109.012484
46. Okada Y, Maeno E, Shimizu T, Dezaki K, Wang J, Morishima S. Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). *J Physiol* (2001) 532:3–16. doi:10.1111/j.1469-7793.2001.0003g.x
47. Voets T, Szucs G, Droogmans G, Nilius B. Blockers of volume-activated Cl⁻ currents inhibit endothelial cell proliferation. *Pflugers Arch* (1995) 431:132–4. doi:10.1007/BF00374387
48. Schumacher PA, Sakellaropoulos G, Phipps DJ, Schlichter LC. Small-conductance chloride channels in human peripheral T lymphocytes. *J Membr Biol* (1995) 145:217–32. doi:10.1007/BF00232714
49. Ullrich N, Sontheimer H. Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. *Am J Physiol* (1996) 270:C1511–21. doi:10.1152/ajpcell.1996.270.5.C1511
50. Shen MR, Droogmans G, Eggermont J, Voets T, Ellory JC, Nilius B. Differential expression of volume-regulated anion channels during cell cycle progression of human cervical cancer cells. *J Physiol* (2000) 529:385–94. doi:10.1111/j.1469-7793.2000.00385.x
51. Wondergem R, Gong W, Monen SH, Dooley SN, Gonce JL, Conner TD, et al. Blocking swelling-activated chloride current inhibits mouse liver cell proliferation. *J Physiol* (2001) 532:661–72. doi:10.1111/j.1469-7793.2001.0661e.x
52. Rouzaire-Dubois B, Malo M, Milandri JB, Dubois JM. Cell size-proliferation relationship in rat glioma cells. *Glia* (2004) 45:249–57. doi:10.1002/glia.10320
53. Renaudo A, L'Hoste S, Guizouarn H, Borgese F, Soriani O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl⁻ channels. *J Biol Chem* (2007) 282:2259–67. doi:10.1074/jbc.M607915200
54. He D, Luo X, Wei W, Xie M, Wang W, Yu Z. DCPIB, a specific inhibitor of volume-regulated anion channels (VRACs), inhibits astrocyte proliferation and cell cycle progression via G_i/S arrest. *J Mol Neurosci* (2012) 46:249–57. doi:10.1007/s12031-011-9524-4
55. Lee EL, Shimizu T, Ise T, Numata T, Kohno K, Okada Y. Impaired activity of volume-sensitive Cl⁻ channel is involved in cisplatin resistance of cancer cells. *J Cell Physiol* (2007) 211:513–21. doi:10.1002/jcp.20961
56. Poulsen KA, Andersen EC, Hansen CF, Klausen TK, Hougaard C, Lambert IH, et al. Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels. *Am J Physiol Cell Physiol* (2010) 298:C14–25. doi:10.1152/ajpcell.00654.2008
57. Sorensen BH, Thorsteinsdottir UA, Lambert IH. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. *Am J Physiol Cell Physiol* (2014) 307:C1071–80. doi:10.1152/ajpcell.00274.2014
58. Shimizu T, Numata T, Okada Y. A role of reactive oxygen species in apoptotic activation of volume-sensitive Cl⁻ channel. *Proc Natl Acad Sci U S A* (2004) 101:6770–3. doi:10.1073/pnas.0401604101
59. Porcelli AM, Ghelli A, Zanna C, Valente P, Ferroni S, Rugolo M. Apoptosis induced by staurosporine in ECV304 cells requires cell shrinkage and upregulation of Cl⁻ conductance. *Cell Death Differ* (2004) 11:655–62. doi:10.1038/sj.cdd.4401396
60. Okada Y, Shimizu T, Maeno E, Tanabe S, Wang X, Takahashi N. Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. *J Membr Biol* (2006) 209:21–9. doi:10.1007/s00232-005-0836-6
61. Sorensen BH, Nielsen D, Thorsteinsdottir UA, Hoffmann EK, Lambert IH. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. *Am J Physiol Cell Physiol* (2016) 310:C857–73. doi:10.1152/ajpcell.00256.2015
62. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. *Cancer Res* (2001) 61:5843–9.
63. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. *Cell Death Differ* (2004) 11:448–57. doi:10.1038/sj.cdd.4401359
64. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* (2008) 321:1807–12. doi:10.1126/science.1164382
65. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. *Semin Cancer Biol* (2009) 19:188–97. doi:10.1016/j.semcancer.2009.02.005

66. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR. Glioma pathophysiology: insights emerging from proteomics. *Brain Pathol* (2010) 20:691–703. doi:10.1111/j.1750-3639.2010.00376.x
67. Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. *Biochim Biophys Acta* (2015) 1848:2685–702. doi:10.1016/j.bbame.2014.12.016
68. Pardo LA, Stuhmer W. The roles of K⁺ channels in cancer. *Nat Rev Cancer* (2014) 14:39–48. doi:10.1038/nrc3635
69. Chen WL, Barszczyk A, Turlova E, Deurloo M, Liu B, Yang BB, et al. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion. *Oncotarget* (2015) 6:16321–40. doi:10.18632/oncotarget.3872
70. D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, et al. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. *Oncotarget* (2016) 7:30781–96. doi:10.18632/oncotarget.8761
71. Wong R, Chen W, Zhong X, Rutka JT, Feng ZP, Sun HS. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion. *J Cell Physiol* (2018) 233:363–70. doi:10.1002/jcp.25891
72. Olsen ML, Schade S, Lyons SA, Amaral MD, Sontheimer H. Expression of voltage-gated chloride channels in human glioma cells. *J Neurosci* (2003) 23:5572–82. doi:10.1523/JNEUROSCI.23-13-05572.2003
73. Wang R, Gurguis CI, Gu W, Ko EA, Lim I, Bang H, et al. Ion channel gene expression predicts survival in glioma patients. *Sci Rep* (2015) 5:11593. doi:10.1038/srep11593

Conflict of Interest Statement: The authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Rubino, Bach, Schober, Lambert and Mongin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.